• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >Maastricht Ⅱ treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori
【24h】

Maastricht Ⅱ treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori

机译：MaastrichtⅡ治疗方案和不同质子泵抑制剂在根除幽门螺杆菌中的功效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: The Maastricht Ⅱ criteria suggest the use of amoxicillin and clarithromycin in addition to a proton pump inhibitor over 7-10 d as a first line therapy in the eradication of Helicobacter pylori (H pylori). For each proton pump inhibitor, various rates of eradication have been reported. The present study was to compare the efficacy of different proton pump inhibitors like omeprazole, lansoprazole and pantoprazole in combination with amoxicillin and clarithromycin in the first line eradication of H pylori and to investigate the success of H pylori eradication in our district. METHODS: A total of 139 patients were included having a Helicobacter pylori (+) gastroduodenal disorders diagnosed by means of histology and urease test. Besides amoxicillin (1 000 mg twice a day) and clarithromycin (500 mg twice a day), they were randomized to take omeprazole (20 mg twice a day), or lansoprazole (30 mg twice a day), or pantoprozole (40 mg twice a day) for 14 d. Four weeks after the therapy, the eradication was assessed by means of histology and urease test. It was evaluated as eradicated if the H pylori was found negative in both. The complaints (pain in epigastrium, nocturnal pain, pyrosis and bloating) were graded in accordance with the Licert scale. The compliance of the patients was recorded. RESULTS: The eradication was found to be 40.8% in the omeprazole group, 43.5% in the lansoprazole group and 47.4% in the pantoprazole group. Sixty-three out of 139 patients (45%) had eradication. No statistically significant difference was observed between the groups. Significant improvements were seen in terms of the impact on the symptom scores in each group. CONCLUSION: There was no difference between omeprazole, lansoprazole and pantoprazole in H pylori eradication, and the rate of eradication was as low as 45%. Symptoms were improved independent of the eradication in each treatment group. The low eradication rates suggest that the antibiotic resistance or the genetic differences of the microorganism might be in effect. Further studies are required to verify these suggestions.
机译：目的：MaastrichtⅡ标准建议在7-10 d内除质子泵抑制剂外还使用阿莫西林和克拉霉素作为根除幽门螺杆菌（H pylori）的一线治疗。对于每种质子泵抑制剂，已经报道了各种根除率。本研究旨在比较不同质子泵抑制剂如奥美拉唑，兰索拉唑和pan托拉唑联合阿莫西林和克拉霉素在幽门螺杆菌一线根除中的效果，并研究在本地区根除幽门螺杆菌的成功性。方法：总共139例患者通过组织学和尿素酶测试诊断为幽门螺杆菌（+）胃十二指肠疾病。除了阿莫西林（每天两次1000毫克）和克拉霉素（每天两次500毫克）外，它们被随机分配服用奥美拉唑（每天两次20毫克），兰索拉唑（每天两次30毫克）或泛醇（两次40毫克）。一天）14天。治疗后四周，通过组织学和脲酶测试评估根除情况。如果在两个病例中均发现幽门螺杆菌阴性，则将其根除。根据Licert量表对主诉（上腹部疼痛，夜间疼痛，发热和腹胀）进行评分。记录患者的依从性。结果：奥美拉唑组的根除率为40.8％，兰索拉唑组为43.5％，pan托拉唑组为47.4％。 139名患者中有63名（45％）已根除。两组之间没有观察到统计学上的显着差异。在对各组症状评分的影响方面，可以看到明显的改善。结论：奥美拉唑，兰索拉唑和pan托拉唑在根除幽门螺杆菌方面没有差异，根除率低至45％。在每个治疗组中症状的改善均与根除无关。较低的根除率表明可能产生了抗生素耐药性或微生物的遗传差异。需要进一步研究以验证这些建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号